Submitted by Michael Frankfort @mfrank_76
Click HERE for a link to the full article.
Scientists are leveraging mRNA technology, initially proven effective against COVID-19, to develop a lung cancer vaccine called BTN116. Developed by BioNTech, this vaccine has entered phase 1 clinical trials in seven countries, including the U.S. and the U.K. The vaccine targets non-small cell lung cancer (NSCLC), the most common form of lung cancer.
Dr. Siow Ming Lee, a consultant medical oncologist at University College London Hospitals, highlights that lung cancer is the leading cause of cancer deaths worldwide. The mRNA vaccine aims to identify and target cancer cells, complementing existing treatments like chemotherapy and immunotherapy. Phase 1 trials are being conducted at 34 research sites across seven countries, with the U.S. recruiting patients at various stages of the disease.
In Canada, lung cancer is the most diagnosed cancer and the leading cause of cancer deaths. The mRNA technology, which trains the immune system to target cancer cells, could represent a significant advancement in cancer treatment. The development of BTN116 began four years ago, following the success of COVID-19 mRNA vaccines. The vaccine requires multiple doses, with the goal of eradicating cancer and preventing its return. However, it is still in the early stages of clinical trials, with phase 2 expected to begin in 2025.
Image created with Microsoft Co-Pilot